These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25897549)

  • 1. Netupitant/palonosetron (Akynzeo) for chemotherapy-induced nausea and vomiting.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):61-3. PubMed ID: 25897549
    [No Abstract]   [Full Text] [Related]  

  • 2. Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?
    Andrews PLR
    Ann Oncol; 2014 Jul; 25(7):1258-1259. PubMed ID: 24942276
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.
    Abramovitz RB; Gaertner KM
    J Oncol Pharm Pract; 2016 Jun; 22(3):477-84. PubMed ID: 25914408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
    Lorusso V; Karthaus M; Aapro M
    Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
    Navari RM
    Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Yeh YC; Blouin GC; Reddy P
    Am J Health Syst Pharm; 2014 Mar; 71(6):500-6. PubMed ID: 24589541
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
    Darmani NA; Zhong W; Chebolu S; Mercadante F
    Pharmacol Biochem Behav; 2015 Apr; 131():104-11. PubMed ID: 25687374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Netupitant-palonosetron combination approved by FDA.
    Thompson CA
    Am J Health Syst Pharm; 2014 Dec; 71(23):2000. PubMed ID: 25404586
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
    Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatments in chemotherapy-induced nausea and vomiting.
    Grunberg SM; Slusher B; Rugo HS
    Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
    Natale JJ; Spinelli T; Calcagnile S; Lanzarotti C; Rossi G; Cox D; Kashef K
    J Oncol Pharm Pract; 2016 Jun; 22(3):485-95. PubMed ID: 25998320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives.
    Rittenberg CN
    Clin J Oncol Nurs; 2004 Jun; 8(3):307-8, 310. PubMed ID: 15208825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution.
    Behbahany K; Bubalo J
    J Oncol Pharm Pract; 2021 Jul; 27(5):1284-1286. PubMed ID: 33100182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
    Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
    Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status of the use of palonosetron.
    Navari R
    Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.